Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Company also announces new name and leadership slate.
January 11, 2022
By: Tim Wright
Editor-in-Chief, Contract Pharma
Performance Cell Manufacturing (PCM), a contract development and manufacturing organization (CDMO) with more than 15 years of experience in manufacturing cell therapies, has been acquired by Great Point Partners (GPP), a Greenwich, CT-based private investment firm focused on the healthcare industry. As part of the deal, the company also announced that it will operate under a new name: Cellipont Bioservices. This is the latest in a series of CDMO investments by Great Point Partners. The firm has also made investments in other CDMOs, including Cytovance Biologics, MaSTherCell, Tergus Pharma and Bionova Scientific. “The Cellipont Bioservices team continues to demonstrate their ability to deliver for clients with an unwavering commitment to quality as its top priority,” said Noah Rhodes, managing director, Great Point Partners. “Across their process development and manufacturing services, the team shares both scientific depth and a steadfast dedication to client service. We were impressed with the business from the first meeting that we had with founder Bob Harman, and we look forward to supporting the Cellipont team as it expands its offerings to help deliver promising new cell therapies to patients.” Cellipont Bioservices’ board of directors has appointed Deborah Wild as president and CEO and Will James as chief financial officer. Carolyn Wrightson, who has served as chief operating officer for the predecessor company for more than 15 years, will continue in that role. Ms. Wild said, “As we shift into the next chapter of the company’s existence, we felt rebranding was important to reflect the essence of our team and mission. By combining ‘cell’ with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of our vision: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. We are excited to reintroduce Cellipont Bioservices to the industry over the coming months.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !